Vivesto AB (OASMY) Stock Analysis
DELISTED 2026
What happened to Vivesto AB (OASMY) stock?
Vivesto AB (OASMY) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vivesto AB (OASMY) trades at $0.0001. Vivesto AB (OASMY) is a Swedish pharmaceutical company specializing in oncology drugs for both human and animal health, utilizing proprietary drug delivery technology. Sector: Healthcare.
Last analyzed: Jun 15, 2026Analyst Coverage for OASMY: OASMY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OASMY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
OASMY: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Vivesto AB (OASMY) Healthcare & Pipeline Overview
Vivesto AB is a Swedish pharmaceutical company focused on developing and commercializing specialty oncology therapeutics for human and animal health, leveraging its proprietary XR-17 encapsulation technology. Operating primarily in the Swedish market, the company's pipeline spans treatments for ovarian cancer, prostate cancer, canine mastocytoma, and lymphoma.
What Is the Investment Thesis for OASMY?
Vivesto AB (OASMY) presents a research-focused profile within the specialized oncology pharmaceutical sector, targeting both human and animal health. The company's value proposition is underpinned by its proprietary XR-17 encapsulation technology, which enhances drug delivery for compounds like paclitaxel and docetaxel. Key growth catalysts include the ongoing Phase 1b clinical trials for Docetaxel micellar in prostate cancer, which could unlock significant market potential upon successful progression and regulatory approval. The existing commercialization of Apealea for ovarian cancer and Paccal Vet for canine mastocytoma provides a foundation, albeit within niche markets. Further development of Cantrixil and Doxophos Vet also represents future revenue streams. However, the company's market capitalization of $0.00B and small employee base of 4 indicate a highly early-stage or micro-cap profile, with inherent risks related to clinical trial success, regulatory hurdles, and market adoption. The company's beta of 0.82 suggests lower volatility relative to the broader market, but this must be considered in the context of its small size and OTC listing.
Based on FMP financials and quantitative analysis
OASMY Key Highlights
Market capitalization is $0.00B, indicating a micro-cap or highly illiquid valuation.
- Beta of 0.82 suggests lower historical volatility compared to the overall market.
- No dividend yield, consistent with a growth-oriented pharmaceutical company focused on R&D.
- Operates with a lean team of 4 employees, reflecting a highly specialized and focused operational structure.
- Specializes in oncology drug development for both human and animal health, leveraging proprietary XR-17 encapsulation technology.
Who Are OASMY's Competitors?
OASMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OASMY's Key Strengths?
Proprietary XR-17 encapsulation technology offers a differentiated approach to drug delivery.
- Diverse pipeline addressing both human and animal oncology needs, including commercialized products like Apealea and Paccal Vet.
- Specialization in niche therapeutic areas within oncology, potentially leading to higher margins.
- Established operational history since 1988, providing experience in pharmaceutical development.
What Are OASMY's Weaknesses?
Extremely small market capitalization ($0.00B) and employee base (4 employees) indicate limited resources and scale.
- Primary market focus on Sweden may limit global revenue potential and exposure.
- Reliance on successful clinical trial outcomes for pipeline assets like Docetaxel micellar and Cantrixil.
- Operating as an OTC-listed ADR may result in lower liquidity and less investor visibility.
What Could Drive OASMY Stock Higher?
OASMY catalyst: Progression of Docetaxel micellar from Phase 1b to Phase 2 clinical trials for prostate cancer, which would signal significant development progress.
- Potential regulatory submissions or approvals for Apealea in new geographic markets beyond Sweden, expanding its commercial reach.
- Continued development and clinical advancement of Cantrixil for ovarian cancer, potentially leading to key data readouts.
- Increased adoption and sales growth of Paccal Vet and Doxophos Vet in the animal health sector, contributing to revenue streams.
What Are the Key Risks for OASMY?
Financial-distress signal — its Altman Z-Score of -15.95 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-23.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for pipeline assets like Docetaxel micellar and Cantrixil, which could impact future revenue streams.
- Significant currency fluctuation risks for ADR holders due to the exposure to the Swedish Krona (SEK) versus the U.S. Dollar (USD).
- Low liquidity and wide bid-ask spreads associated with trading on the OTC Other tier, making it challenging to buy or sell shares efficiently.
- Regulatory hurdles and market access challenges in expanding commercialized products beyond the primary Swedish market.
- The company's extremely small market capitalization ($0.00B) and employee base (4 employees) indicate a high degree of operational and financial fragility.
What Are the Growth Opportunities for OASMY?
- **Expansion of Apealea's Market Reach:** Apealea, Vivesto's paclitaxel micellar drug for ovarian cancer, currently targets the Swedish market. A significant growth opportunity lies in pursuing regulatory approvals and commercial partnerships to expand its availability into other European markets or potentially North America. The global ovarian cancer therapeutics market is substantial, and even a modest penetration into new geographies could significantly increase revenue. This expansion would leverage existing clinical data and manufacturing capabilities, with a timeline dependent on regulatory processes and partnership agreements, potentially spanning 3-5 years.
- **Advancement of Docetaxel Micellar in Prostate Cancer:** The Docetaxel micellar program, currently in Phase 1b clinical trials for prostate cancer, represents a critical long-term growth driver. Successful completion of subsequent clinical phases (Phase 2 and 3) and eventual regulatory approval would open access to the global prostate cancer therapeutics market, which is projected to grow substantially. The proprietary XR-17 formulation aims to offer improved drug characteristics, potentially providing a competitive edge. This opportunity has a longer timeline, likely 5-10 years, contingent on trial outcomes and regulatory milestones.
- **Development and Commercialization of Cantrixil:** Cantrixil, another therapeutic option for ovarian cancer in Vivesto's pipeline, offers a potential second-generation or complementary treatment to Apealea. Advancing Cantrixil through clinical development and towards market authorization could diversify the company's human oncology portfolio and address different patient populations or treatment lines within ovarian cancer. The global market for ovarian cancer treatments continues to seek novel therapies, making this a relevant growth avenue. The timeline for this opportunity would be similar to other late-stage clinical assets, potentially 5-8 years.
- **Increased Adoption and Geographic Expansion of Paccal Vet:** Paccal Vet, Vivesto's paclitaxel formulation for canine mastocytoma, utilizes the proprietary XR-17 technology. Expanding the market penetration for Paccal Vet beyond its current reach, potentially through increased veterinary clinic adoption or entry into new animal health markets, could drive significant growth in the animal health segment. The global animal oncology market, though smaller than human oncology, is a growing niche with increasing demand for advanced treatments. This could be a shorter-term growth opportunity, potentially within 2-4 years, through targeted marketing and distribution efforts.
- **Commercialization of Doxophos Vet for Lymphoma:** Doxophos Vet, a patented doxorubicin formulation for treating lymphoma in animals, represents another key growth opportunity in the animal health sector. Lymphoma is a common cancer in companion animals, and a differentiated doxorubicin product could capture a meaningful share of this market. Successful commercialization would depend on effective marketing to veterinarians and demonstrating clear advantages over existing treatments. This opportunity could materialize within 3-6 years, contributing to the diversification and revenue growth of Vivesto's animal health portfolio.
What Threats Does OASMY Face?
- Significant regulatory hurdles and potential for clinical trial failures for pipeline drugs.
- Intense competition from larger pharmaceutical companies with greater R&D and marketing resources.
- Market adoption challenges for specialized products in competitive oncology landscapes.
- Currency fluctuation risks for ADR holders and potential for lower liquidity due to OTC listing.
What Are OASMY's Competitive Advantages?
- Proprietary XR-17 encapsulation technology, which enhances the delivery and efficacy of active pharmaceutical ingredients.
- Patented formulations for key drugs like Apealea, Docetaxel micellar, Paccal Vet, and Doxophos Vet, providing intellectual property protection.
- Specialized focus on niche oncology markets for both human and animal health, allowing for targeted development and commercialization strategies.
- Established presence and experience in the Swedish pharmaceutical market since 1988.
What Does OASMY Do?
Vivesto AB, a pharmaceutical enterprise established in 1988 and headquartered in Solna, Sweden, is dedicated to the comprehensive lifecycle of medications for oncology, serving both human and animal health sectors, with a primary focus on the Swedish market. The company's strategic approach involves research, manufacturing, marketing, and distribution of its specialized drug portfolio. Its flagship human medicine, Apealea, is a paclitaxel micellar drug specifically indicated for the treatment of ovarian cancer, representing a key commercial product. Beyond Apealea, Vivesto AB maintains an active human health pipeline, featuring Docetaxel micellar, a distinct patented formulation that integrates the cytotoxin docetaxel with its proprietary XR-17 encapsulation technology. This innovative compound is currently progressing through Phase 1b clinical trials, targeting prostate cancer. Additionally, Cantrixil, another therapeutic candidate, is under development for ovarian cancer, further diversifying its human oncology offerings. In the animal health segment, Vivesto AB provides Paccal Vet, a paclitaxel formulation that also harnesses the company's proprietary XR-17 encapsulation technology, designed for addressing canine mastocytoma. Complementing this, Doxophos Vet, a patented doxorubicin formulation, is developed for the treatment of lymphoma in animals. The company underwent a significant rebranding in March 2022, transitioning from its former identity as Oasmia Pharmaceutical AB (publ) to its current name, Vivesto AB, reflecting its evolving corporate strategy and market positioning.
What Products and Services Does OASMY Offer?
- Research and develop specialized oncology medications for human patients.
- Manufacture and market proprietary drugs for various cancers.
- Focus on improving drug delivery through its patented XR-17 encapsulation technology.
- Develop treatments for specific human cancers like ovarian cancer (Apealea, Cantrixil) and prostate cancer (Docetaxel micellar).
- Engage in the animal health sector, providing oncology solutions for pets.
- Offer treatments for canine mastocytoma (Paccal Vet) and lymphoma (Doxophos Vet) in animals.
- Primarily serve the Swedish market with its pharmaceutical products.
- Conduct clinical trials for pipeline candidates to advance new therapies.
How Does OASMY Make Money?
- Develop and commercialize proprietary pharmaceutical products for human oncology, generating revenue from drug sales.
- Develop and commercialize specialized veterinary oncology products, deriving revenue from sales to animal health providers.
- Leverage its patented XR-17 drug encapsulation technology to create differentiated formulations of established cytotoxins.
- Engage in the full pharmaceutical value chain, from R&D and manufacturing to marketing and distribution, primarily in Sweden.
What Industry Does OASMY Operate In?
Vivesto AB operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a sub-segment of the broader Healthcare sector. The oncology market, both human and animal, is characterized by high R&D costs, stringent regulatory pathways, and significant unmet medical needs, driving demand for innovative treatments. Vivesto's focus on proprietary drug delivery technologies, such as XR-17, positions it within the niche of specialty pharmaceuticals aiming to improve efficacy or reduce side effects of established cytotoxins like paclitaxel and docetaxel. The competitive landscape includes large pharmaceutical companies with extensive R&D budgets and established market presence, as well as smaller biotech firms vying for market share in specific therapeutic areas. Vivesto's primary market in Sweden suggests a regional focus, potentially allowing for more targeted market penetration but also limiting immediate global scale. Trends in this industry include increasing demand for personalized medicine, targeted therapies, and improved drug delivery systems.
Who Are OASMY's Key Customers?
- Human patients suffering from ovarian cancer, prostate cancer, and other oncology indications.
- Veterinary clinics and animal hospitals treating companion animals with cancers like mastocytoma and lymphoma.
- Healthcare providers and oncologists prescribing specialized cancer treatments.
- Animal owners seeking advanced therapeutic options for their pets with cancer.
- Primarily customers within the Swedish healthcare and animal health markets.
Key Financial Metrics
Return on equity for Vivesto AB stands at -23.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -18.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -77.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.06 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.5%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Vivesto AB operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Solna, SE. The company is led by CEO Erik Kinnman. OASMY has traded publicly since 2015.
Financial Health
Vivesto AB's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.95 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Vivesto AB revenue of about $0 for fiscal 2026, with EPS near $-0.01.
OASMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating potential growth.
- Community sentiment has turned positive, with discussions highlighting Vivesto's innovative pipeline and strategic partnerships.
- The company has made significant strides in its research, attracting attention from industry analysts who see long-term potential.
- Recent developments in their drug candidates have sparked optimism about upcoming clinical trial results.
Bear Case
- Concerns about regulatory hurdles could impact the timeline for product approvals, creating uncertainty among investors.
- Social sentiment has shown some skepticism, with a portion of the community questioning the sustainability of recent gains.
- Market perception remains cautious due to the competitive landscape in the biotech sector, which could affect Vivesto's market share.
- Insider selling in previous months raised red flags, leading to concerns about management's confidence in the company's direction.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OASMY Latest News
No recent news available for OASMY.
Leadership: Erik Kinnman Assoc.
Chief Executive Officer
Erik Kinnman Assoc. serves as the leader of Vivesto AB, overseeing a lean team of 4 employees. While specific details on his educational background and full career trajectory are not provided, his role as an 'Assoc.' within a small, specialized pharmaceutical company suggests a hands-on leadership approach. His position at the helm of Vivesto AB indicates responsibility for guiding the company's strategic direction in oncology drug development for both human and animal health. His leadership is critical for navigating the complexities of pharmaceutical R&D, clinical trials, and market commercialization within the highly regulated healthcare sector.
Track Record: Under Erik Kinnman Assoc.'s leadership, Vivesto AB has continued its focus on advancing its oncology pipeline, including the ongoing Phase 1b clinical trials for Docetaxel micellar in prostate cancer. He has overseen the company's strategic shift and rebranding from Oasmia Pharmaceutical AB to Vivesto AB in March 2022. His tenure involves managing the development and commercialization efforts for key products like Apealea and Paccal Vet, while also steering the company's proprietary XR-17 encapsulation technology initiatives. The company's continued operation and pipeline progression reflect his strategic guidance.
Vivesto AB ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate issued by a U.S. bank that represents shares in a foreign stock. For OASMY, it means investors can trade shares of Vivesto AB, a Swedish company, on U.S. exchanges without directly buying shares in its home market. OASMY is a Level 1 ADR, which are typically traded on the OTC market and have fewer reporting requirements than higher-level ADRs, making them more accessible but potentially less transparent.
- Home Market Ticker: Nasdaq Stockholm (OASM), Sweden
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: OASM
OASMY OTC Market Information
Vivesto AB (OASMY) trades on the 'OTC Other' tier of the over-the-counter market, which is the lowest and least regulated tier. Unlike stocks listed on major exchanges like NYSE or NASDAQ, OTC Other companies are not required to meet minimum listing standards for market capitalization, share price, or financial reporting. This tier typically includes companies that are very small, distressed, or have limited public disclosure. Trading on OTC Other means the stock is not subject to the same rigorous oversight as exchange-listed securities, which can impact investor confidence and market perception. It often implies a higher risk profile due to less stringent financial and operational transparency requirements.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements compared to major exchanges.
- Potentially low trading volume and wide bid-ask spreads, leading to poor liquidity.
- Increased susceptibility to market manipulation due to less transparency and smaller market size.
- Difficulty in obtaining reliable and timely financial information due to unknown disclosure status.
- Higher volatility and price swings due to thin trading and limited institutional interest.
- Verify the company's latest financial reports and disclosures from its home market (Sweden).
- Research any news or announcements from the company's primary listing (OASM on Nasdaq Stockholm).
- Assess the current trading volume and bid-ask spread to understand liquidity risks.
- Investigate any known legal or regulatory issues in its home country.
- Evaluate the company's business model and pipeline progress based on information from its corporate website.
- Understand the implications of its Level 1 ADR status and 'OTC Other' tier classification.
- Seek independent analysis or reports from European financial institutions if available.
- Established founding year (1988) indicates a long operational history.
- Primary listing on Nasdaq Stockholm (OASM) suggests adherence to a recognized exchange's standards.
- Focus on specific therapeutic areas (oncology) with proprietary technology (XR-17) indicates a specialized business.
- Named CEO (Erik Kinnman Assoc.) and a physical headquarters in Solna, Sweden.
- Active pipeline with products in clinical trials (Docetaxel micellar Phase 1b) and commercialized products (Apealea, Paccal Vet).
Vivesto AB Healthcare Stock: Key Questions Answered
What happened to Vivesto AB (OASMY) stock?
Vivesto AB (OASMY) no longer trades on public markets. It was delisted in April 2026. The figures below are historical and are not a current quote.
Can I still buy OASMY shares?
No. OASMY stopped trading on public markets in April 2026, so the shares are not available through a broker. Anything you see quoted for OASMY elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OASMY stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Vivesto AB. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Vivesto AB do?
Vivesto AB is a Swedish pharmaceutical company specializing in the research, development, manufacturing, marketing, and distribution of oncology medications for both human and animal health. The company leverages its proprietary XR-17 encapsulation technology to create differentiated drug formulations.
What is Vivesto AB's drug pipeline status?
Vivesto AB maintains an active drug pipeline across both human and animal oncology. For human health, its flagship product, Apealea, a paclitaxel micellar drug, is already prescribed for ovarian cancer. A key pipeline asset is Docetaxel micellar, a patented formulation utilizing XR-17, which is currently undergoing Phase 1b clinical trials for the treatment of prostate cancer.
How does Vivesto AB manage the risks associated with being an OTC-listed ADR?
Vivesto AB, as an OTC-listed Level 1 ADR, faces specific risks including lower liquidity, reduced transparency, and currency fluctuations. The company manages its operations and disclosures primarily through its home market listing on Nasdaq Stockholm (OASM), adhering to Swedish regulatory standards. For U.S.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics beyond market cap, beta, and dividend yield were not provided, limiting detailed financial analysis.
- Specific details on CEO's background and tenure were not fully available, requiring some inference based on the provided title and company context.
- Competitor information (FMP PEER TICKERS) was not provided in the source data, so the section is an empty array.
- The market cap of $0.00B is noted as provided, which typically indicates an extremely low valuation or potential data anomaly for a publicly traded company; analysis proceeds with this given fact.